Genetic mutation test kit SPG-CRC001

colorectal cancerfor genomicsfor BRAF mutations

Product Name: Colorectal Cancer Related Gene Mutation Detection Kit Pack Size:16 Tests/Kit 32 Tests/Kit Instruments Validated:Illumina Sample Type:Tumor tissue, Ascites Targeted Drugs and Immunotherapy : KRAS,NRAS,BRAF,PIK3CA,ERBB2,MSI Prognosis Related Genes: TP53 Chemosensitivity Gene: UGT1A1,DYPD NGS method detected 6 genes related to targeted drugs and immunosuppressants KRAS, NRAS, BRAF, PIK3CA, TP53, ERBB2, 34 MSI loci and 2 chemotherapy related genes UGT1A1 and DYPD at one time to guide the individual drug regimen of colorectal patients. DETECTION SIGNIFICANCE 1.It contains KRAS, NRAS, BRAF, PIK3CA and ERBB2 genes, covering the sensitive and drug-resistant sites of Cetuximab, Trastuzumab, Pertuzumab, Lapatinib, panitumumab and other colorectal cancer targeted drugs related to sensitivity and resistance; 2.It contains marker MSI site of immunosuppressant Pembrolizumab 3.It contains UGT1A1 and DYPD genes related to chemotherapy, which can adjust the medication of irinotecan, fluorouracil, capecitabine and Ftorafur.The level of evidence for the effectiveness of chemotherapy genes can refer to PharmGKB database; 4.It includes TP53 tumor suppressor gene detection, which provides reference for patient prognosis evaluation and inclusion in AZD1775 clinical trial; 5.The MSI site adopts single nucleotide site, which effectively avoids the problem of polynucleotide polymorphism and can meet the detection of single sample MSI;